{
  "ticker": "JNJ",
  "target_date": "2025-08-27",
  "actual_date": "2025-08-27",
  "collected_at": "2025-12-08T12:11:49.355082",
  "price": {
    "open": 175.85,
    "high": 176.57,
    "low": 175.05,
    "close": 175.67459106445312,
    "volume": 5951100,
    "change_1d_pct": 0.17,
    "change_7d_pct": 1.04,
    "change_30d_pct": 8.08
  },
  "technicals": {
    "rsi_14": 76.39,
    "sma_20": 171.99,
    "sma_50": 162.7,
    "macd": 3.786,
    "macd_signal": 3.966,
    "macd_histogram": -0.181,
    "bb_upper": 180.09,
    "bb_lower": 163.89,
    "price_vs_sma20_pct": 2.14,
    "price_vs_sma50_pct": 7.98,
    "volume_ratio": 0.69
  },
  "fundamentals": {
    "market_cap": 488123203584,
    "pe_ratio": 19.555986,
    "forward_pe": 19.113207,
    "price_to_book": 6.1492705,
    "price_to_sales": 5.296326,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.52,
    "pct_from_52w_low": 43.99
  },
  "macro": {
    "spy": {
      "price": 644.84,
      "change_1d_pct": 0.23,
      "change_7d_pct": 1.07
    },
    "vix": {
      "level": 14.85,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.24
    },
    "dollar_index": {
      "level": 98.23
    },
    "gold": {
      "price": 3404.6
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "What Is the Intent Behind AbbVie's Recent Acquisition Spree?",
      "source": "Yahoo",
      "datetime": 1756307820,
      "summary": "ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.",
      "url": "https://finnhub.io/api/news?id=eb09f7dbdfaa9734efc1d66217ea368d21397abd4e2c31f020e5200ae80b5436"
    },
    {
      "headline": "Best Dividend Aristocrats For September 2025",
      "source": "SeekingAlpha",
      "datetime": 1756303789,
      "summary": "Discover top Dividend Aristocrats for 2025! Explore undervalued picks with 10%+ annualized returns, robust payout growth, and reliable income opportunities.",
      "url": "https://finnhub.io/api/news?id=6fa72cb3c60dde4a3180ad17c2df91d58aa59ccc934dd1f72334c03464c353e0"
    },
    {
      "headline": "Will Camzyos Strengthen BMY's Cardiovascular Portfolio?",
      "source": "Yahoo",
      "datetime": 1756303500,
      "summary": "Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.",
      "url": "https://finnhub.io/api/news?id=6dd2c50f4ff131f4e4e9576cb60563591f4426ac4f6caf4c37bf354484d278e3"
    },
    {
      "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
      "source": "Yahoo",
      "datetime": 1756284600,
      "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market g",
      "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be"
    },
    {
      "headline": "Autism Spectrum Disorder Market Research Report 2025-2035 | Expansion Spurred by Rising Prevalence, AI-Powered Diagnostics, Telehealth Expansion, and Adoption of Evidence-Based Therapies",
      "source": "Yahoo",
      "datetime": 1756284240,
      "summary": "Autism Spectrum Disorder (ASD) involves challenges in social interaction, communication, and repetitive behaviors. Early diagnosis is enhanced by advancements in screening tools and genetic testing, increasing the demand for personalized therapies. FDA-approved medications for irritability in ASD, R",
      "url": "https://finnhub.io/api/news?id=fd997815a653213df602c31c2d03e9d6818c7bc6bed0987151aae7401d0f2e9e"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-08-25",
      "description": "xslF345X05/wk-form4_1756163533.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000182/xslF345X05/wk-form4_1756163533.xml"
    },
    {
      "form": "4",
      "date": "2025-08-18",
      "description": "xslF345X05/wk-form4_1755555550.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000180/xslF345X05/wk-form4_1755555550.xml"
    },
    {
      "form": "10-Q",
      "date": "2025-07-24",
      "description": "jnj-20250629.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000178/jnj-20250629.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-07-22",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000367/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-07-18",
      "description": "xslF345X05/wk-form4_1752869553.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000172/xslF345X05/wk-form4_1752869553.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}